UNLABELLED: We evaluated potential associations between maximum standardized uptake value (SUV(max)) on (18)F-FDG PET before and after radiation therapy (RT) and survival outcomes for patients with locally advanced non-small cell lung cancer. METHODS: Patients with stage III non-small cell lung cancer (n = 49) who had undergone (18)F-FDG PET at the M.D. Anderson Cancer Center both before and up to 3.5 mo after undergoing radiochemotherapy were studied; exclusion criteria were patients with a history of thoracic surgery, RT, or other cancer or those who had received a total radiation dose less than 60 Gy. We assessed associations between overall survival (OS) or disease-free survival (DFS) and post-RT SUV(max) and the extent of decrease in SUV(max) in the primary tumor (PT) and regional lymph nodes (LNs). SUV(max) was assessed as a continuous variable by Cox proportional hazards regression analysis. RESULTS: Univariate and multivariate analyses showed that having a high post-RT SUV(max) (either PT or LNs) was associated with a higher risk of death (univariate analyses: hazard ratio [HR] for PT SUV(max), 1.27, P < 0.0001; HR for LN SUV(max), 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV(max), 1.16, P = 0.004; HR for LN SUV(max), 1.32, P = 0.001). Moreover, after definitive RT, the greater the decrease in SUV(max) in the lesion that had the highest SUV(max) at diagnosis, the longer the OS (HR, 0.06; P = 0.002), DFS (HR, 0.03; P = 0.001), local-regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028). CONCLUSION: The post-RT SUV(max) in both the PT and the LNs was a predictor of survival-specifically, the higher the residual SUV(max) after RT, the poorer the OS and DFS; and the greater the decrease in SUV(max) in the lesion with the highest SUV(max) at diagnosis, the longer the OS and DFS. This information should help to identify patients who are at high risk of recurrence and for whom additional treatments can be designed accordingly.
UNLABELLED: We evaluated potential associations between maximum standardized uptake value (SUV(max)) on (18)F-FDG PET before and after radiation therapy (RT) and survival outcomes for patients with locally advanced non-small cell lung cancer. METHODS:Patients with stage III non-small cell lung cancer (n = 49) who had undergone (18)F-FDG PET at the M.D. Anderson Cancer Center both before and up to 3.5 mo after undergoing radiochemotherapy were studied; exclusion criteria were patients with a history of thoracic surgery, RT, or other cancer or those who had received a total radiation dose less than 60 Gy. We assessed associations between overall survival (OS) or disease-free survival (DFS) and post-RT SUV(max) and the extent of decrease in SUV(max) in the primary tumor (PT) and regional lymph nodes (LNs). SUV(max) was assessed as a continuous variable by Cox proportional hazards regression analysis. RESULTS: Univariate and multivariate analyses showed that having a high post-RT SUV(max) (either PT or LNs) was associated with a higher risk of death (univariate analyses: hazard ratio [HR] for PT SUV(max), 1.27, P < 0.0001; HR for LN SUV(max), 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV(max), 1.16, P = 0.004; HR for LN SUV(max), 1.32, P = 0.001). Moreover, after definitive RT, the greater the decrease in SUV(max) in the lesion that had the highest SUV(max) at diagnosis, the longer the OS (HR, 0.06; P = 0.002), DFS (HR, 0.03; P = 0.001), local-regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028). CONCLUSION: The post-RT SUV(max) in both the PT and the LNs was a predictor of survival-specifically, the higher the residual SUV(max) after RT, the poorer the OS and DFS; and the greater the decrease in SUV(max) in the lesion with the highest SUV(max) at diagnosis, the longer the OS and DFS. This information should help to identify patients who are at high risk of recurrence and for whom additional treatments can be designed accordingly.
Authors: Jay P Reddy; Chad Tang; Tina Shih; Bumyang Kim; Charissa Kim; Quynh-Nhu Nguyen; James Welsh; Marcelo Benveniste; Jianjun Zhang; Zhongxing Liao; Daniel R Gomez Journal: Clin Lung Cancer Date: 2016-11-10 Impact factor: 4.785
Authors: Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink Journal: Nat Rev Clin Oncol Date: 2015-04-28 Impact factor: 66.675
Authors: A J Conde-Moreno; J L Lopez-Guerra; V A Macias; M L Vázquez de la Torre; P Samper Ots; S San José-Maderuelo; J Pastor Peidro; J López-Torrecilla; J Expósito-Hernández Journal: Clin Transl Oncol Date: 2015-09-02 Impact factor: 3.405